(Q44841358)

6 December 2017

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma (English)

1 reference

6 December 2017

1 reference

1 reference

4

1 reference

6 December 2017

6

1 reference

6 December 2017

1

S T Holgate

1 reference

6 December 2017

A G Chuchalin

2

1 reference

6 December 2017

J Hébert

3

1 reference

6 December 2017

G B Persson

5

1 reference

6 December 2017

J Bousquet

7

1 reference

6 December 2017

H A Kerstjens

8

1 reference

6 December 2017

H Fox

9

1 reference

6 December 2017

J Thirlwell

10

1 reference

6 December 2017

G Della Cioppa

11

1 reference

6 December 2017

Omalizumab 011 International Study Group

12

1 reference

6 December 2017

1 April 2004

1 reference

Clinical & Experimental Allergy

6 December 2017

1 reference

6 December 2017

34

1 reference

6 December 2017

632-638

1 reference

6 December 2017

4

1 reference

Costs of asthma according to the degree of severity.

6 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2004.1916.X

Conformation of the isolated cepsilon3 domain of IgE and its complex with the high-affinity receptor, FcepsilonRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2004.1916.X

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2004.1916.X

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2004.1916.X

Interpreting treatment effects in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2004.1916.X

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2004.1916.X

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2004.1916.X

Difficult/therapy‐resistant asthmaThe need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2004.1916.X

10.1111/J.1365-2222.2004.1916.X

21 January 2018

Identifiers

DOI

1 reference

release_chyshvojhfbhdn3i5jsmr3d5le

6 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/chyshvojhfbhdn3i5jsmr3d5le

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference